Imvax
PA - PhiladelphiaBiotechnology
Focus: Imvax is a Philadelphia-based biotechnology company specializing in personalized vaccines and immunotherapy for infectious diseases. Founded in 2004, the company operates as a public-stage biotech focused on next-generation vaccine development.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$29M
Open Jobs
0
About Imvax
AI assessmentNot HiringNo open roles listed right now. Follow Imvax to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
IGV-001 Cell Immunotherapy
GlioblastomaClinical Trials (1)
NCT04485949A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Phase 2Help build intelligence for Imvax
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.